CR20170177A - Diamino-quinoleína 2,4 sustituida como nuevos agentes anticancerígenos - Google Patents

Diamino-quinoleína 2,4 sustituida como nuevos agentes anticancerígenos

Info

Publication number
CR20170177A
CR20170177A CR20170177A CR20170177A CR20170177A CR 20170177 A CR20170177 A CR 20170177A CR 20170177 A CR20170177 A CR 20170177A CR 20170177 A CR20170177 A CR 20170177A CR 20170177 A CR20170177 A CR 20170177A
Authority
CR
Costa Rica
Prior art keywords
quinoleína
banker
diamino
agents
replaced
Prior art date
Application number
CR20170177A
Other languages
English (en)
Inventor
Gregory Nicolas
Philippe Halfon
Clarisse Dubray
Sonia Brun
Firas Bassissi
Antoine Beret
Jérome Courcambeck
Original Assignee
Genoscience Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genoscience Pharma filed Critical Genoscience Pharma
Publication of CR20170177A publication Critical patent/CR20170177A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El presente invento se relaciona a derivados novedosos de amino-quinoleína 2-primario amino-4-secundario, su manufactura, composiciones farmacéuticas que los comprendan y su uso como medicamentos. Los compuestos activos de la presente invención son útiles para el tratamiento y prevención de enfermedades proliferativas neoplásicas y no neoplásicas.
CR20170177A 2014-10-31 2015-10-26 Diamino-quinoleína 2,4 sustituida como nuevos agentes anticancerígenos CR20170177A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462073325P 2014-10-31 2014-10-31
PCT/IB2015/002438 WO2016067112A1 (en) 2014-10-31 2015-10-26 Substituted 2,4 diamino-quinoline as new anticancer agents

Publications (1)

Publication Number Publication Date
CR20170177A true CR20170177A (es) 2017-09-19

Family

ID=55404745

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170177A CR20170177A (es) 2014-10-31 2015-10-26 Diamino-quinoleína 2,4 sustituida como nuevos agentes anticancerígenos

Country Status (34)

Country Link
US (1) US10722505B2 (es)
EP (1) EP3212629B1 (es)
JP (1) JP6588546B2 (es)
KR (1) KR102548547B1 (es)
CN (1) CN107148416B (es)
AU (1) AU2015338844B2 (es)
CA (1) CA2965262C (es)
CL (1) CL2017001073A1 (es)
CO (1) CO2017007325A2 (es)
CR (1) CR20170177A (es)
CY (1) CY1121326T1 (es)
DK (1) DK3212629T3 (es)
DO (1) DOP2017000107A (es)
EA (1) EA037119B1 (es)
EC (1) ECSP17026748A (es)
ES (1) ES2707125T3 (es)
GE (1) GEP20207108B (es)
HR (1) HRP20190107T1 (es)
IL (1) IL251775B (es)
LT (1) LT3212629T (es)
MA (1) MA40875B1 (es)
MY (1) MY193740A (es)
NI (1) NI201700052A (es)
PE (1) PE20191142A1 (es)
PH (1) PH12017500810A1 (es)
PL (1) PL3212629T3 (es)
PT (1) PT3212629T (es)
RS (1) RS58328B1 (es)
SG (1) SG11201703479SA (es)
SI (1) SI3212629T1 (es)
TN (1) TN2017000168A1 (es)
TR (1) TR201900148T4 (es)
UA (1) UA122062C2 (es)
WO (1) WO2016067112A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3452465T3 (da) * 2016-05-04 2021-02-08 Genoscience Pharma Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
EP3620164A1 (en) 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
FI3873903T3 (fi) 2018-10-31 2024-03-26 Gilead Sciences Inc Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2022033465A1 (zh) * 2020-08-10 2022-02-17 萧乃文 具有协同抗癌功效的氯硝柳胺和双硫仑医药组合物及其用途
CN112375081B (zh) * 2020-11-23 2022-04-12 中国医学科学院医药生物技术研究所 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
CN112876673B (zh) * 2021-01-25 2021-12-24 山东大学 一种pH响应性纳米共聚物载体及其制备方法和应用
EP4349336A1 (en) 2022-10-04 2024-04-10 Genoscience Pharma Combination of substituted 2,4 diamino-quinoline compounds and mek inhibitors for use in the treatment of liver cancers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8580301A1 (es) * 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
AU2003288994A1 (en) * 2002-12-10 2004-06-30 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
JP2006519846A (ja) * 2003-03-10 2006-08-31 シェーリング　コーポレイション 複素環式キナーゼインヒビター：使用および合成の方法
WO2014113388A1 (en) * 2013-01-15 2014-07-24 Incyte Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
MX2015013396A (es) * 2013-03-18 2016-07-08 Genoscience Pharma Derivados de quinolinas como nuevos agentes contra el cancer.

Also Published As

Publication number Publication date
EP3212629A1 (en) 2017-09-06
DK3212629T3 (en) 2019-02-18
IL251775B (en) 2020-07-30
CN107148416B (zh) 2020-05-05
AU2015338844A1 (en) 2017-05-04
IL251775A0 (en) 2017-06-29
PE20191142A1 (es) 2019-09-02
GEP20207108B (en) 2020-05-11
EA037119B1 (ru) 2021-02-09
CN107148416A (zh) 2017-09-08
WO2016067112A1 (en) 2016-05-06
US20190314359A1 (en) 2019-10-17
TN2017000168A1 (en) 2018-10-19
CA2965262A1 (en) 2016-05-06
PL3212629T3 (pl) 2019-05-31
MA40875A (fr) 2017-09-06
TR201900148T4 (tr) 2019-02-21
PT3212629T (pt) 2019-02-04
NZ731345A (en) 2023-09-29
LT3212629T (lt) 2019-01-10
JP6588546B2 (ja) 2019-10-09
CA2965262C (en) 2023-03-14
NI201700052A (es) 2017-09-11
CL2017001073A1 (es) 2018-01-12
ECSP17026748A (es) 2018-03-31
UA122062C2 (uk) 2020-09-10
MY193740A (en) 2022-10-27
RS58328B1 (sr) 2019-03-29
CO2017007325A2 (es) 2017-10-20
HRP20190107T1 (hr) 2019-03-08
EA201790949A1 (ru) 2018-02-28
KR102548547B1 (ko) 2023-06-27
ES2707125T3 (es) 2019-04-02
JP2017538673A (ja) 2017-12-28
US10722505B2 (en) 2020-07-28
SI3212629T1 (sl) 2019-02-28
PH12017500810A1 (en) 2017-10-02
AU2015338844B2 (en) 2019-09-19
SG11201703479SA (en) 2017-05-30
MA40875B1 (fr) 2019-01-31
DOP2017000107A (es) 2017-09-15
CY1121326T1 (el) 2020-05-29
GEAP202014494A (en) 2020-01-27
EP3212629B1 (en) 2018-10-24
BR112017018637A2 (pt) 2022-07-05
KR20170077160A (ko) 2017-07-05

Similar Documents

Publication Publication Date Title
DOP2017000107A (es) Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
SV2016005257A (es) Benzimidazol-2-aminas como inhibidores de midh1
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
DOP2017000278A (es) Piridinas sustituidas y método de uso
SV2016005351A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
ECSP16074478A (es) Compuestos novedosos
CO2018007278A2 (es) Derivados de ácido aminobenzoico metaazacíclico como antagonistas de la integrina pan
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
CR20180256A (es) Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
GT201700016A (es) [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CO2017009989A2 (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda
DOP2016000161A (es) Ureas asimétricas p- sustituidas y usos médicos de las mismas.
CU20180044A7 (es) Derivados novedosos de diamino piridina